PD50 Certainty Of Evidence Assessment Of The BRIGHTE Study: Fostemsavir In The Treatment Of Multidrug-Resistant HIV-1
Marina Silva, Isabela Rossi, Lívia Nassif, Roberto Júnior, Ludmila Gargano, Juliana Alvares-Teodoro, Francisco Acurcio, Augusto Guerra Júnior · 2025
Read PD50 Certainty Of Evidence Assessment Of The BRIGHTE Study: Fostemsavir In The Treatment Of Multidrug-Resistant HIV-1 by Marina Silva, Isabela Rossi, Lívia Nassif, Roberto Júnior, Ludmila Gargano, Juliana Alvares-Teodoro, Francisco Acurcio, Augusto Guerra Júnior (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768836.txt.
Description
Marina Silva and co-authors wrote a 2025 study that grades the strength of proof behind a trial of an HIV drug. The drug, fostemsavir, was tested in adults whose HIV no longer responded to standard drugs. In the trial, called BRIGHTE, some patients were assigned by chance to the drug or a dummy pill for eight days.
After those eight days, all patients moved to the drug, and the trial turned into plain follow-up. The team used a standard grading tool on five reports from the trial, covering checks out to 240 weeks. They found that the shift to open follow-up weakened the design and raised the risk of bias. Proof from the first eight days was also cut by study flaws. The study warns readers to weigh late results from this trial with care.
Catalog record
| CREATOR | Marina Silva, Isabela Rossi, Lívia Nassif, Roberto Júnior, Ludmila Gargano, Juliana Alvares-Teodoro, Francisco Acurcio, Augusto Guerra Júnior |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |